To gain insight in the total Costs of fi rst-line treatment of NSCLC phase III/IV in the Dutch hospital setting. To calculate the budget impact of adding Iressa (gefi tinib), including EGFR mutation testing, to the treatment sequence. To identify costs of EGFR mutation testing. METHODS: A budget impact model was constructed by Medaxial and adapted by AstraZeneca the The Netherlands to better refl ect the Dutch situation. The model calculates the budget impact of EGFR testing and the resulting therapy change for NSCLC patients in Dutch hospitals. The model covers the fi rst-line treatment of NSCLC fase IIIb/IV patients and calculates total costs in a hospital setting and budget impact, taken into account the following costs-Medication-EGFR mutation testing-Administration and monitoring-Treating grade III/ IV adverse events. The model also calculates-Costs of delivery of oral therapies (outside hospital costs). RESULTS: Before introduction of Iressa, total costs of fi rstline NSCLC treatment in Dutch hospitals was c41,982.936. After introduction of Iressa, total costs in hospital setting slightly decreased to c41.939,604 (year 1). Cost of EGFR mutation testing is c198,432, but medication costs of the hospital will decrease with c248,193. CONCLUSIONS: Adding extra diagnosis will introduce new costs to the NSCLC treatment. However, for an individual hospital, the extra costs are limited. And the total costs of fi rst-line NSCLC treatment even decrease, since the reimbursement of Iressa is outside of the hospital budget. As a result, the hospital has less costs if patients are tested and the appropriate patients then treated with Iressa. At the moment, for some hospitals, EGFR mutation testing is still seen as a hurdle. Apart from the ethical point of view (making sure patients will receive the medication they will benefi t most from), also from costs perspective, it is worth to test.
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INFLUENCE OF ME-TOOS TO POSSIBLE SAVINGS DUE TO BIOSIMILARS
Fuezi J, Reichardt B Sickness Fund Burgenland, Eisenstadt, Burgenland, Austria OBJECTIVES: To avoid the waste of market shares, me-toos of established top-selling biopharmaceuticals enter the market before their patent expiry. After switching the sales to the me-too, called "step-innovation" by the provider, the possible savings of biosimilars diminish as the sales are parked at the me-toos. The objective of the study is to analyze this hypothesis for the two2 substance classes erythropoiesis-stimulating agents (ESA) and granulocyte colony-stimulating factors (G-CSF). METHODS: By analyzing the account data of regional Austrian sickness funds, the share of prescriptions of fi lgrastim in GCSF (fi lgrastim plus lenograstim plus pegfi lgrastim) and of epoetin in ESA (epoetin plus darbepoetin) are correlated to the costs per package. These data are shown for several periods, 6 months before the availability of Biosimilars, 6 montha after their availability, and 2 further half-years for ESA. To take regional infl uence into consideration, the data are shown for all nine regional sickness funds of Austria. RESULTS: The shares of prescription for epoetin in ESA show a huge regional dispersion from 42% to 88% and those of fi lgrastim in GCSF from 23% to 66%. The average costs per package have an inverse relation to their market share. These data are reconfi rmed through data of the other periods. The average costs per package have been declined with increased market share of the biosimilars. The infl uence of the market share of the me-toos is though overwhelming. CONCLU-SIONS: For pharmaceutical companies, it is a profi t-maximizing strategy to substitute their products in time before patent expiry. The less the substitution by patent-protected alternatives succeeds, the higher the achievable cost saving potential for the sickness funds is.
PCN39 COST UTILITY OF HUMAN PAPILOMA VIRUS VACCINE IN SPAIN
Callejo D, Lopez-Polin A, Blasco JA Agencia Lain Entralgo, Madrid, Spain OBJECTIVES: It is well known that a persistent infection by human papillomavirus (HPV) is an essential cause of cervical cancer. Prophylactic HPV vaccines aimed at preventing precancerous cervical lesions and cervical cancer are currently available and may be used for primary prevention of cervical cancer. To defi ne the effi ciency of using HPV vaccine within a cervical cancer screening program with cytology compared with the strategy of only screening with cytology. METHODS: A comprehensive search of studies was developed in the main electronic databases including primary studies assessing HPV vaccine effi cacy and/or safety or HPV. Meta-analysis was conducted when the studies were homogeneous. a decision analysis was performed using a Markov model based on the results of the systematic review and information about the natural history of the disease (HPV infection, cervical cancer). The model allowed to estimate cancer incidence and associated mortality, life expectancy, and associated costs, with the objective of performing an economic evaluation. RESULTS: A total of 11 studies were included to assess HPV vaccines: seven for effi cacy and 11 for safety assessment. The effi cacy of vaccine in preventing CIN2+ was 96% (95% CI: 91% to 98%). Modifi ed intention-to-treat and intention-to-treat analyses were also undertaken and the results supported this trend, although effi cacy was lower. The economic evaluation showed that the vaccination strategy would imply a cost-effectiveness ratio of around c10,000 per quality-life adjusted-years (QALY). CONCLU-SIONS: There is evidence from RCTs that the HPV vaccines are safe and effective in the prevention of cervical cancer precursor lesions. On top of this, this effi cacy is reached with a reasonable cost-effectiveness ratio and within the accepable limits of the Spanish National Health System. The burden of metastatic renal cell carcinoma (mRCC) is substantial for patients and society. Bevacizumab (BEV) combination with interferon alfa-2a (IFN) has demonstrated to prolong mRCC patients' progression-free survival and to have comparable effi cacy to sunitinib (SUN). However, tolerability differs between these treatment alternatives and it is therefore of importance to evaluate the economic impact of adverse events (AEs) management, for each alternative, in the daily clinical practice in Portugal. METHODS: A linear decision analytical model was applied considering direct medical costs only in the Portuguese Health System perspective. AEs incidences associated with each of the two alternatives were extracted from published literature. Health resource consumption was estimated based on an expert panel of Portuguese oncologists and urologists. Corresponding unitary costs were obtained through national offi cial sources. The considered time horizon was 1 year. The basecase analysis includes all grades AEs and a normal dose (nine MUI, three times weekly) of IFN scenario. Deterministic univariate sensitivity analyses were performed to test the robustness of the model including grade 3-4 AEs analysis only and IFN low-dose (six MUI or three MUI, three times weekly) scenarios. RESULTS: The associated costs of managing AEs were considerably lower with BEV + IFN than with SUN in Portugal. The average treatment costs for all grade AEs per patient was c1472 for SUN and c1093 for BEV + IFN resulting in a difference of −379 c (a cost saving of 26% for BEV + IFN vs. SUN). Sensitivity analyses showed that BEV + IFN remains the less costly option when alternative scenarios are considered and that a low-dose IFN would lead even to further cost savings. CONCLUSIONS: BEV + IFN is a more tolerable and hence cost-saving alternative for the Portuguese Health System considering the AE management costs of mRCC treatment when compared to SUN. These results are consistent with previous evidence for other countries.
PCN40 COST ANALYSIS OF MANAGING ADVERSE EVENTS IN THE
PCN41 ECONOMIC OUTCOMES AMONG 2ND LINE NON-SMALL CELL LUNG CANCER PATIENTS IN THE OUTPATIENT COMMUNITY SETTING
Gruschkus S 1 , Reyes C 2 , Forsyth M 1 , Ravelo A 2 , Nadler E 1 1 US Oncology, The Woodlands, TX, USA; 2 Genentech, Inc., South San Francisco, CA, USA OBJECTIVES: Second-line monotherapy options for advanced NSCLC include erlotinib (E), docetaxel (D), or pemetrexed (P). The purpose of this retrospective study was to compare economic outcomes among patients (pts) receiving 2nd line monotherapy in the outpatient community setting. METHODS: Using US Oncology's iKnowMed EMR data, we identifi ed advanced NSCLC patients who received 2nd line monotherapy from July 1, 2006 to June 30, 2008 . Economic outcomes were derived using outpatient claims and pharmacy data and included total outpatient, chemotherapy, supportive care costs, and frequency of outpatient physician visits, lab procedures, and acute care (ER/inpatient) visits. All economic outcomes were calculated as per-patient month (PPM) metrics over a 12-month follow-up period. Multiple regression analyses were used to estimate the independent association between treatment (E, D, or P) on outcomes after controlling for age, gender, stage at diagnosis, baseline hemoglobin, and performance status. RESULTS: We identifi ed 610 pts-73 received E, 87 received D, and 450 received P. Total cost, chemotherapy costs, and supportive care costs differed signifi cantly by treatment, as did frequency of outpatient visits and lab procedures. Relative to P, total adjusted costs PPM is $1579 lower for D and $1584 lower for E (P < 0.05). Majority of the cost savings are due to decreased chemo-related costs. Outpatient visits, lab procedures, and acute care visits are also less frequent with E relative to P (−2.6 PPM, P < 0.05). CONCLUSIONS: In US outpatient setting, pts receiving E and D have statistically signifi cant lower costs and resource use relative to pts receiving P.
PCN42 COSTS OF MANAGING ADVERSE EVENTS OF FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO: BEVACIZUMAB IN COMBINATION WITH INTERFERON-ALPHA-2A COMPARED WITH SUNITINIB
Carlos F, Ramirez J, Aguirre A R a C Salud Consultores S.A. de C.V., México, D.F., Mexico OBJECTIVES: Bevacizumab plus interferon-α2a (BEV+IFN) prolongs progressionfree survival (PFS) to >10 months, providing comparable effi cacy to sunitinib in patients with metastatic renal cell carcinoma (mRCC). However, the type and frequency of adverse events (AE) differ between these two regimens. We aimed to assess the costs of managing AE of grade 3/4 of these regimens from the perspective of public health-care system in Mexico. METHODS: A linear decision analytic model was developed to compare the direct medical costs of managing AE of grade 3/4 of BEV + IFN and sunitinib in patients with mRCC. AE of grade 1/2 are assumed to entail
